Alternative Therapies for Menopause: A Randomized Trial
NCT ID: NCT00061711
Last Updated: 2009-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
355 participants
INTERVENTIONAL
2000-07-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary aim of this randomized, controlled trial is to compare the effects of three alternative treatments utilizing phytoestrogens, HRT, and placebo on the frequency and intensity of vasomotor symptoms measured by the Wiklund Menopause Symptom Checklist and daily vasomotor symptom diaries. The alternative treatments chosen for the study are a single herbal formula of black cohosh, a multibotanical formula containing black cohosh, alfalfa, boron, chasteberry, dong quai, false unicorn, licorice, oats, pomegranate, and Siberian ginseng, and soy diet counseling in addition to the multibotanical formula.
The findings of the Women's Health Initiative study published in July 2002 gave the medical and research communities new information about the long-term risk of HRT use. In response to these findings, the study design allows women to be randomized either to the 5-arm trial that includes HRT, or to be randomized only to 4 of the 5 arms: one of the three herbal groups or placebo, without the chance of being assigned to HRT.
Secondary aims are to compare the effects of three alternative treatments, HRT, and placebo on:
1. vaginal cytology (vaginal maturation index)
2. serum lipids (total cholesterol, HDL and LDL cholesterol, triglycerides)
3. bone mineral density (hip and spine dual energy x-ray absorptiometry scan)
4. glucose metabolism (insulin, fasting blood glucose)
5. clotting factors (fibrinogen, PAI-1).
Approximately 400 peri- and post-menopausal women will be recruited and randomized to one of 5 or one of 4 treatment arms for one year. Primary and secondary outcomes will be measured at baseline, 3, 6, and 12 months. Changes in outcomes will be compared between the groups taking alternative treatments and those in the HRT and placebo groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hormone Replacement Therapy
Cimicifuga racemosa (Black Cohosh)
Multibotanical phytoestrogen formula
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Peri- or post-menopausal, defined as having no menstrual periods for at least 12 months prior to study entry, or skipping at least one menstrual period in the 12 months prior to study entry. Peri- or post-menopausal status will be determined for candidates who have had the uterus removed by an assessment of blood follicle stimulating hormone (FSH). Women with an FSH level higher than 20 mlU/mL will be eligible for the study.
3. Experiencing an average of 2 or more hot flashes or night sweats per day, of which 6 or more must be of moderate or greater intensity over two weeks.
4. Normal thyroid stimulating hormone (TSH) measured prior to study entry, defined as 0.4 - 5.0 ulU/ML.
5. Proof of negative mammogram within two years prior to randomization. Subjects may provide copies of the mammogram results or a letter from their primary care provider.
6. Must provide informed consent.
7. Not at high risk for medical complications that might affect the subject's ability to complete the trial without a serious co-morbid event, based on medical history, physical examination and laboratory screening evaluation.
Exclusion Criteria
2. Use of hormone replacement therapy or oral contraceptives within the past three months.
3. Use of alternative or complementary medicines or herbs for menopausal symptoms within the past one month.
4. History of any illness or having significant abnormalities on prestudy clinical or laboratory evaluation such that in the opinion of the investigator participating in this study might pose an unacceptable risk to the subject.
5. The subject has a medical history of any of the following contraindications to HRT: breast cancer, uterine cancer, endometrial hyperplasia, angina treated with medication, myocardial infarction, revascularization surgery, coronary angioplasty, stroke, blood clots, active chronic liver disease, or nephrotic syndrome.
6. Bone mineral density of the hip or spine more than two standard deviations below the age-specific mean.
7. bilateral oophorectomy.
8. Current use of any of the following medications: tamoxifen, raloxifene, bisphosphonates, cholesterol-lowering medications, prescription blood-thinners, or oral steroids.
9. Pregnant or planning to become pregnant.
10. Baseline blood pressure greater than 160/95 mm Hg.
11. Alergy to soybeans or soy protein.
12. Unable to swallow pills.
13. Current participation in another investigational drug trial.
14. Intention to move within the next 12 months rendering follow-up per the protocol impossible.
15. Noncompliance in the procedures involved with the screening visit or run-in trial. To be compliant, subjects must take at least 80% of the run-in medication (can miss 2-1/2 days) and complete at least 80% of the baseline symptom diaries (can miss 3 days of the hot flash and night sweats diaries, must complete all Wiklund checklists).
45 Years
55 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Health Studies Research Clinic
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol. 2002 Jul;100(1):18-25. doi: 10.1016/s0029-7844(02)02005-7.
Phelan EA, Buist DS, Anderson LA, Newton KM, Delaney KM, LaCroix AZ. Understanding attitudes of older women toward hormone replacement therapy. Prev Med. 2001 Jan;32(1):49-56. doi: 10.1006/pmed.2000.0768.
Newton KM, LaCroix AZ, Leveille SG, Rutter C, Keenan NL, Anderson LA. Women's beliefs and decisions about hormone replacement therapy. J Womens Health. 1997 Aug;6(4):459-65. doi: 10.1089/jwh.1997.6.459.
Newton KM, LaCroix AZ, Buist DS, Keenan NL. The use of alternative and complementary medicine by women enrolled in an HMO setting. Menopause, 1998, 5:244.
Newton KM, Reed SD, Grothaus L, Ehrlich K, Guiltinan J, Ludman E, Lacroix AZ. The Herbal Alternatives for Menopause (HALT) Study: background and study design. Maturitas. 2005 Oct 16;52(2):134-46. doi: 10.1016/j.maturitas.2005.01.007.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AG0003
Identifier Type: -
Identifier Source: org_study_id